secwatch.observer — SEC 8-K summary
======================================

Issuer:     Opus Genetics, Inc. (IRD)
CIK:        0001228627
Form:       8-K
Filed at:   2025-08-25T23:59:59+00:00
Accession:  0001140361-25-032533
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 3.02
LLM model:  deepseek-v4-flash:cloud@v2

Opus Genetics raises $3.5M in private placement led by board chair for gene therapy manufacturing
--------------------------------------------------------------------------------

- Issued 3,138,338 shares at ~$1.11/sh in private placement; gross proceeds $3.5M.
- Led by board chair Cam Gallagher ($1M) and lead independent director Sean Ainsworth.
- Proceeds to expedite manufacturing process development for gene therapy candidates OPGx-LCA5 and OPGx-BEST1.
- Private placement closed August 25, 2025; exempt under Section 4(a)(2) and Regulation D.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1228627/000114036125032533/0001140361-25-032533-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1228627/000114036125032533/ef20054479_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-25-032533

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer